Try our new research platform with insights from 80,000+ expert users
Microsoft Defender for Business Logo

Microsoft Defender for Business Reviews

Vendor: Microsoft
3.8 out of 5

What is Microsoft Defender for Business?

Featured Microsoft Defender for Business reviews

Microsoft Defender for Business mindshare

Product category:
As of March 2025, the mindshare of Microsoft Defender for Business in the Endpoint Protection Platform (EPP) category stands at 1.9%, up from 1.2% compared to the previous year, according to calculations based on PeerSpot user engagement data.
Endpoint Protection Platform (EPP)

PeerAnalyst reports based on Microsoft Defender for Business reviews

TypeTitleDate
CategoryEndpoint Protection Platform (EPP)Mar 4, 2025Download
ProductReviews, tips, and advice from real usersMar 4, 2025Download
ComparisonMicrosoft Defender for Business vs Microsoft Defender for EndpointMar 4, 2025Download
ComparisonMicrosoft Defender for Business vs CrowdStrike FalconMar 4, 2025Download
ComparisonMicrosoft Defender for Business vs SentinelOne Singularity CompleteMar 4, 2025Download
Suggested products
TitleRatingMindshareRecommending
CrowdStrike Falcon4.311.2%96%126 interviewsAdd to research
Microsoft Defender for Endpoint4.011.1%94%190 interviewsAdd to research
 
 
Key learnings from peers

Valuable Features

Room for Improvement

ROI

Pricing

Popular Use Cases

Service and Support

Deployment

Scalability

Stability

Review data by company size

By reviewers
By visitors reading reviews

Top industries

By visitors reading reviews
Computer Software Company
18%
Comms Service Provider
7%
Retailer
7%
Government
6%
Manufacturing Company
6%
Financial Services Firm
5%
Educational Organization
5%
Non Profit
5%
Hospitality Company
4%
University
4%
Insurance Company
4%
Healthcare Company
3%
Real Estate/Law Firm
3%
Construction Company
3%
Legal Firm
3%
Energy/Utilities Company
3%
Media Company
3%
Outsourcing Company
3%
Wholesaler/Distributor
2%
Performing Arts
2%
Recreational Facilities/Services Company
1%
Transportation Company
1%
Pharma/Biotech Company
1%